Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/17/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. LMT
7. NVDA
8. USO
9. TLT
10. AMZN

Go back to Taysha Gene Therapies and Catalent Expand Strategic Partnership to Include Future Commercial Manufacturing Support of TSHA-102 Gene Therapy for Rett Syndrome
(NASDAQ: TSHA) Delayed: 5.16 +0.09 (1.78%)
Previous Close $5.07    52 Week High $ 
Open $5.25    52 Week Low $ 
Day High $5.46    P/E N/A 
Day Low $5.05    EPS $ 
Volume 3,147,390       

(NASDAQ: TSHA) Delayed: 5.16 +0.09 (1.78%)
Previous Close $5.07    52 Week High $ 
Open $5.25    52 Week Low $ 
Day High $5.46    P/E N/A 
Day Low $5.05    EPS $ 
Volume 3,147,390